Table 1 Demographic data of patients undergoing curative surgery
Patient | Sex | Age (y) | Diagnosis | Child class (score) | Tumor marker | Location of hepatic tumor | Thrombi location | Pre-operative therapy |
|---|---|---|---|---|---|---|---|---|
1 | F | 68 | Leiomyosarcoma of IVC with liver invasion | Non-cirrhosis | N/A | Seg 1,2,3 | Reaching the hepatocaval junction | N |
2 | F | 46 | HBV-related HCC | A (5) | AFP: 5000 ng/dL | Seg 7,8 | Near the hepatocaval junction | N |
3 | M | 57 | HBV-related HCC | A (6) | AFP: 4000 ng/dL | seg 5,6,7,8 | Reaching the hepatocaval junction | N |
4 | F | 38 | Adrenocortical carcinoma with liver | Non-cirrhosis | N/A | seg 4,5,6,7,8 | Reaching the hepatocaval junction | N |
5 | M | 72 | HBV-related HCC | A (5) | AFP: >40 000 ng/dL | seg 4,5,6,7,8 | Near the hepatocaval junction | N |
6 | M | 46 | HBV-related HCC | A (5) | AFP: >40 000 ng/dL | seg 7 | Near the hepatocaval junction | N |
7 | M | 29 | HBV-related HCC | A (5) | AFP: >40 000 ng/dL | seg 5,6,7,8 | Near the hepatocaval junction | N |
8 | M | 46 | HBV-related HCC | A (5) | AFP: >40 000 ng/dL | seg 6,7,8 | Reaching the hepatocaval junction | TACE + Sorafenib |
9 | M | 86 | Non-HBV or –HCV-related HCC, sacromatoid type | A (5) | AFP: 2.29 ng/dL | seg 4 | Reaching the hepatocaval junction | TACE + Sorafenib |
10 | M | 40 | HBV-related HCC | A (5) | AFP: 168.5 ng/dL | seg 5,6 | Reaching the hepatocaval junction | TACE + Sorafenib |
Mean | Â | 52.8 | Â | Â | Â | Â | Â | Â |
SD | Â | 17.7 | Â | Â | Â | Â | Â | Â |